5 Einträge gefunden

1. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

   1. Weisel, Katja
   2. Dimopoulos, Meletios A
   3. San-Miguel, Jesús
   4. Paner, Agne
   5. Engelhardt, Monika
   6. Taylor, Fiona
   7. Lord-Bessen, Jennifer

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

   1. Richardson, Paul G
   2. Schjesvold, Fredrik
   3. Weisel, Katja
   4. Moreau, Philippe
   5. Anderson, Larry D
   6. White, Darrell
   7. Rodriguez-Otero, Paula

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

   1. Dimopoulos, Meletios
   2. Weisel, Katja
   3. Moreau, Philippe
   4. Anderson, Larry D
   5. White, Darrell
   6. San-Miguel, Jesus
   7. Sonneveld, Pieter

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

   1. Jansen, Lina
   2. Merz, Maximilian
   3. Engelhardt, Monika
   4. Weisel, Katja
   5. Scheid, Christof
   6. Straka, Christian
   7. Langer, Christian

   2020 - Forschungsinformationssystem des UKE
5. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

   1. Raab, Marc S
   2. Engelhardt, Monika
   3. Blank, Antje
   4. Goldschmidt, Hartmut
   5. Agis, Hermine
   6. Blau, Igor W
   7. Einsele, Hermann

   2020 - Forschungsinformationssystem des UKE